Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24119483 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Stefania Kalogera und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nordic Bioscience, Biomarkers and Research, 2730 Herlev, Denmark. Hauptthemen laut MEDLINE: Osteoarthritis, Knee. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 research and innovation programme, Innovative Medicines Initiative, European Union’s Horizon 2020 research and innovation program.
Abstract (Originalsprache)
The association between structural changes and pain sensation in osteoarthritis (OA) remains unclear. Joint deterioration in OA leads to the release of protein fragments that can either systemically (serum) or locally (synovial fluid; SF) be targeted as biomarkers and describe structural changes and potentially pain. Biomarkers of collagen type I (C1M), type II (C2M), type III (C3M), type X (C10C), and aggrecan (ARGS) degradation were measured in the serum and SF of knee OA patients. Spearman’s rank correlation was used to assess the correlation of the biomarkers’ levels between serum and SF. Linear regression adjusted for confounders was used to evaluate the associations between the biomarkers’ levels and clinical outcomes. The serum C1M levels were negatively associated with subchondral bone density. The serum C2M levels were negatively associated with KL grade and positively associated with minimum joint space width (minJSW). The C10C levels in SF were negatively associated with minJSW and positively associated with KL grade and osteophyte area. Lastly, the serum C2M and C3M levels were negatively associated with pain outcomes. Most of the biomarkers seemed to mainly be associated with structural outcomes. The overall biomarkers of extracellular matrix (ECM) remodeling in serum and SF may provide different information and reflect different pathogenic processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nordic Bioscience, Biomarkers and Research, 2730 Herlev, Denmark.
- Department of Drug Design and Pharmacology, Copenhagen University, 1165 Copenhagen, Denmark.
- Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands.
- Regenerative Medicine Center, Utrecht University, 3584 CS Utrecht, The Netherlands.
ORCID-Profile: Mylène P Jansen, Anne-Christine Bay-Jensen
Förderung
- European Union's Horizon 2020 research and innovation programme
- Innovative Medicines Initiative
- European Union’s Horizon 2020 research and innovation program
- Innovative Medicines Initiative Joint Undertaking
- European Union’s Seventh Framework Programme
- EFPIA companies
Zitieren
APA
Kalogera, S., Jansen, M. P., Bay-Jensen, A. C., Frederiksen, P., Karsdal, M. A., Thudium, C. S., & Mastbergen, S. C. (2023). Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119483
Vancouver
Kalogera S, Jansen MP, Bay-Jensen AC, Frederiksen P, Karsdal MA, Thudium CS, et al. Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119483
BibTeX
@article{Kalogera2023,
author = {Kalogera, Stefania and Jansen, Mylène P and Bay-Jensen, Anne-Christine and Frederiksen, Peder and Karsdal, Morten A and Thudium, Christian S and Mastbergen, Simon C},
title = {Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24119483}
}
EUVIMED